Mortality and Morbidity Among Individuals With Hypertension Receiving a Diuretic, ACE Inhibitor, or Calcium Channel Blocker

医学 利尿剂 噻嗪 内科学 心力衰竭 钙通道阻滞剂 血管紧张素转换酶抑制剂 随机对照试验 临床终点 冠状动脉疾病 心脏病学 血管紧张素转换酶 血压
作者
José‐Miguel Yamal,J. Alfredo Martínez,Mikala C. Osani,Xianglin L. Du,Lara M. Simpson,Barry R. Davis
出处
期刊:JAMA network open [American Medical Association]
卷期号:6 (12): e2344998-e2344998
标识
DOI:10.1001/jamanetworkopen.2023.44998
摘要

Importance The long-term relative risk of antihypertensive treatments with regard to mortality and morbidity is not well understood. Objective To determine the long-term posttrial risk of primary and secondary outcomes among trial participants who were randomized to either a thiazide-type diuretic, calcium channel blocker (CCB), or angiotensin-converting enzyme (ACE) inhibitor with up to 23 years of follow-up. Design, Setting, and Participants This prespecified secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a multicenter randomized, double-blind, active-controlled clinical trial, followed up with participants aged 55 years or older with a diagnosis of hypertension and at least 1 other coronary heart disease risk factor for up to 23 years, from February 23, 1994, to December 31, 2017. Trial participants were linked with administrative databases for posttrial mortality (N = 32 804) and morbidity outcomes (n = 22 754). Statistical analysis was performed from January 2022 to October 2023. Interventions Participants were randomly assigned to receive a thiazide-type diuretic (n = 15 002), a CCB (n = 8898), or an ACE inhibitor (n = 8904) for planned in-trial follow-up of approximately 4 to 8 years and posttrial passive follow-up for up to 23 years. Main Outcomes and Measures The primary end point was mortality due to cardiovascular disease (CVD). Secondary outcomes included all-cause mortality, combined fatal and nonfatal (morbidity) CVD, and both mortality and morbidity for coronary heart disease, stroke, heart failure, end-stage renal disease, and cancer. Results A total of 32 804 participants (mean [SD] age, 66.9 [7.7] years; 17 411 men [53.1%]; and 11 772 Black participants [35.9%]) were followed up for all-cause mortality and a subgroup of 22 754 participants (mean [SD] age, 68.7 [7.2] years; 12 772 women [56.1%]; and 8199 Black participants [36.0%]) were followed up for fatal or nonfatal CVD through 2017 (mean [SD] follow-up, 13.7 [6.7] years; maximum follow-up, 23.9 years). Cardiovascular disease mortality rates per 100 persons were 23.7, 21.6, and 23.8 in the diuretic, CCB, and ACE inhibitor groups, respectively, at 23 years after randomization (adjusted hazard ratio [AHR], 0.97 [95% CI, 0.89-1.05] for CCB vs diuretic; AHR, 1.06 [95% CI, 0.97-1.15] for ACE inhibitor vs diuretic). The long-term risks of most secondary outcomes were similar among the 3 groups. Compared with the diuretic group, the ACE inhibitor group had a 19% increased risk of stroke mortality (AHR, 1.19 [95% CI, 1.03-1.37]) and an 11% increased risk of combined fatal and nonfatal hospitalized stroke (AHR, 1.11 [95% CI, 1.03-1.20]). Conclusions and Relevance In this secondary analysis of a randomized clinical trial in an adult population with hypertension and coronary heart disease risk factors, CVD mortality was similar between all 3 groups. ACE inhibitors increased the risk of stroke outcomes by 11% compared with diuretics, and this effect persisted well beyond the trial period. Trial Registration ClinicalTrials.gov Identifier: NCT00000542
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CipherSage应助mochi采纳,获得10
1秒前
xxw完成签到,获得积分10
2秒前
暄暄发布了新的文献求助10
2秒前
满意的匪完成签到 ,获得积分10
3秒前
沐雨发布了新的文献求助10
3秒前
4秒前
搜集达人应助DARKNESS采纳,获得10
6秒前
善学以致用应助威武冷雪采纳,获得10
8秒前
9秒前
高贵季节发布了新的文献求助10
10秒前
风趣秋白完成签到,获得积分10
11秒前
11秒前
半岛岛发布了新的文献求助10
12秒前
mochi发布了新的文献求助10
14秒前
科研通AI2S应助欢喜发卡采纳,获得10
14秒前
Solar energy发布了新的文献求助10
16秒前
懵懂的愫完成签到 ,获得积分10
16秒前
庸尘完成签到,获得积分10
17秒前
阳和启蛰完成签到,获得积分10
18秒前
Fjj完成签到,获得积分20
19秒前
李健应助无私的鸣凤采纳,获得30
20秒前
bkagyin应助mochi采纳,获得10
22秒前
23秒前
24秒前
可爱邓邓完成签到 ,获得积分10
25秒前
Karinaa发布了新的文献求助10
28秒前
11发布了新的文献求助10
29秒前
李健应助俭朴的世立采纳,获得10
29秒前
沐雨完成签到,获得积分20
30秒前
Liziqi823完成签到,获得积分10
30秒前
skyla1003完成签到 ,获得积分10
37秒前
39秒前
科研通AI2S应助牛诗悦采纳,获得10
44秒前
研友_aLjo9n完成签到,获得积分10
46秒前
46秒前
50秒前
50秒前
醉烟雨完成签到,获得积分10
50秒前
lcc应助东方天奇采纳,获得10
51秒前
陶醉的蜜蜂完成签到 ,获得积分10
52秒前
高分求助中
The Oxford Handbook of Social Cognition (Second Edition, 2024) 1050
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Chen Hansheng: China’s Last Romantic Revolutionary 500
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3140431
求助须知:如何正确求助?哪些是违规求助? 2791320
关于积分的说明 7798479
捐赠科研通 2447661
什么是DOI,文献DOI怎么找? 1302008
科研通“疑难数据库(出版商)”最低求助积分说明 626359
版权声明 601194